CEO: Stephen S. Yoder, J.D.
Headquarters: Boston, Massachusetts
Investment Date: December 2014
APO Financing: $13,600,000
Trading Venue: NASDAQ CM (PIRS)
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.